Benvenue Medical Begins Enrollment in Landmark Study Versus Balloon Kyphoplasty

SANTA CLARA, Calif.–(BUSINESS WIRE)–Benvenue Medical, Inc., a developer of minimally invasive solutions for spine repair, announced today that it has enrolled the first patient into the landmark KAST (Kiva® System as a Vertebral Augmentation Treatment – A Safety and Effectiveness Trial) study. The case was performed by Sean Tutton, MD FSIR, Associate Professor of Radiology and Surgery at the Medical College of Wisconsin in Milwaukee.

The patient was suffering from two painful, osteoporotic vertebral compression fractures (VCF). According to Dr. Tutton, “The patient was treated using the Kiva VCF Treatment System, is doing well, and was discharged pain-free in less than two hours after the procedure. The Kiva System worked well and afforded excellent control of the cement with no evidence of leakage. We are excited to be part of the KAST study and look forward to validating the many possible benefits of this major clinical advancement.”

“The first enrollment in the KAST study is a significant milestone that reflects Benvenue Medical’s continued commitment to advancing the treatment of painful osteoporotic fractures. We have very strong interest and participation in this trial which speaks well to the potential benefits of the Kiva System. Kiva, along with the recent successful introduction of our Blazer Vertebral Augmentation System, give physicians two novel approaches to treat painful VCFs,” said Robert Weigle, CEO of Benvenue Medical.

“The Kiva Implant is a new, innovative device to help treat painful osteoporotic fractures. The KAST trial, which is a randomized, Level-I clinical study comparing the Kiva Implant to kyphoplasty, will determine Kiva’s effectiveness and analyze patient outcomes associated with these two options. Randomized clinical trials are important in guiding decision-making when there are potentially multiple treatment options,” said Steven R. Garfin, M.D., Professor and Chairman, Department of Orthopaedic Surgery at the University of California, San Diego Medical Center.

The Kiva VCF Treatment System is commercially available in Europe. In support of 510(k) marketing clearance from the FDA in the United States, Benvenue Medical is conducting the KAST study, a landmark randomized controlled trial (RCT) versus balloon kyphoplasty. The KAST study is an RCT with 1:1 randomization versus kyphoplasty, with one year of follow-up on patients treated on study. Success will require non-inferiority on the primary endpoint, which is a composite of pain, function, and safety. There is potential to demonstrate superiority on key secondary endpoints including PMMA cement volume, extravasation rate, and subsequent fracture rate as well as other endpoints. Drs. Tutton and Garfin are the lead Co-Principal Investigators in the KAST study.

About Vertebral Compression Fractures and the Kiva VCF Treatment System

The Kiva VCF Treatment System addresses unmet needs of spine surgeons and interventional radiologists that treat this condition. VCF treatment represented a global market of over $640 million and over 200,000 procedures in 2009. The market remains under penetrated with roughly 700,000 additional VCF patients diagnosed each year worldwide. However, only a small percentage of patients currently benefit from minimally invasive techniques due to limitations of the technology currently available.

The Kiva VCF Treatment System provides an innovative approach to the treatment of painful VCFs. The Kiva System preserves cancellous architecture using a percutaneously-introduced PEEK-OPTIMA® cylindrical Implant inserted in a continuous loop fashion. The PEEK implant’s length is physician-customized in-situ based on fracture morphology. The Implant is delivered over a removable guidewire designed to provide structural support to the vertebral body and to serve as a conduit for PMMA bone cement placement. Vertical displacement by the Implant results in endplate re-elevation and fracture reduction. Bone cement is delivered through the lumen of the Implant and into the center of vertebral body, providing interdigitation and preferential flow of the cement towards the endplates. Planar distribution of the bone cement is intended to support the endplates while containment and directional control of the flow of cement minimize extravasation.

In addition to providing pain relief, fracture stabilization and functional improvement, this novel, minimally invasive system is designed to:

  • Reduce PMMA volume
  • Preserve cancellous bone structure
  • Potentially reduce adjacent level fractures
  • Reduce extravasation rate versus comparable technologies

About Benvenue Medical, Inc.

Founded in 2004 and headquartered in Santa Clara, California, Benvenue Medical, Inc. is advancing spine repair through the development of proprietary, minimally invasive surgical and interventional solutions. The company is privately held and funded by DeNovo Ventures and Versant Ventures.

Keywords: spine, spinal, radiology, interventional radiology, interventional neuroradiology, surgery, vertebral augmentation, kyphoplasty, vertebroplasty, VCF, vertebral compression fracture, minimally invasive surgery, back, back pain, clinical trial, research, lumbar, thoracic

Print Friendly, PDF & Email

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button